Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > Avastin (bevacizumab)

Avastin (bevacizumab) : Genentech : Monoclonal antibody

Avastin (bevacizumab) Clinical Research
Avastin (bevacizumab) Side Effects

Avastin (bevacizumab) Clinical Research

Bevacizumab (Avastin) Combined with Chemotherapy Prolongs Survival in Some Patients with NSCLC (National Cancer Institute)
Discusses preliminary results from a large, randomized clinical trial for previously untreated non-squamous cell NSCLC patients that showed bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without Avastin. [5/05]

NSCLC and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? (The Oncologist)
by Roy S. Herbst and Alan B. Sandler
v.9,Suppl.1 The Oncologist (June 1, 2004): 19-26
Explains the process of antiangiogenesis in lung cancer, focusing on the experience with bevacizumab in a promising Phase II trial. Discusses the main toxicity concerns with the use of bevacizumab in NSCLC. [6/04]

Avastin - Recent MEDLINE Abstracts (PubMed)

Avastin Clinical Trials (ClinicalTrials.gov)



Avastin (bevacizumab) Side Effects

Avastin (bevacizumab) (ChemoCare)
Factsheet describes Avastin (bevacizumab), how it is given, possible side effects, precautions and self-care tips. [2005]



 


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor